NIKA Enters the Pharmaceutical Industry
NIKA BIOTECHNOLOGY, INC. ANNOUNCES ITS ENTRY INTO THE PHARMACEUTICAL INDUSTRY AND NEW BUSINESS STRATEGY
LAS VEGAS, NV, August 29, 2022: Newly appointed Chairman and President Dimitar Savov is pleased to announce a change of the business model of the company, which has now switched to the pharmaceutical industry. To reflect the new business scope, the company has changed its name from International Professional Trainings Group, Inc. to Nika BioTechnology, Inc., and its trading symbol from INGP to NIKA. Clifford Redekop becomes company secretary and remains a director.
On August 1, 2022, Nika BioTechnology, Inc. (NIKA) and Nika Pharmaceuticals, Inc. (a Colorado pharmaceutical corporation) signed a cooperation agreement, on which to build upon a successful joint business model for the production and distribution of all current and future medicinal products and nutritional supplements owned by Nika Pharmaceutical. The two companies will invest in the development of the joint business in equal parts and will similarly share the net profits in equal parts.
The joint business model initial focus will be on the development of the medicinal product Thymus Nuclear Glycoprotein (“TNG”), which has passed a successful clinical trial on patients suffering from AIDS, and the dietary supplements Physiolong and Carotilen. You can find more information regarding TNG, Physiolong, and Carotilen on the official website of Nika Pharmaceuticals, Inc. (www.nikapharmaceuticals.com). We expect to also have that information available on the brand-new website of Nika BioTechnology, which would reflect the new pharmaceutical corporate identity and should launch by September 5, 2022.
Nika BioTechnology will acquire 40% stake in Nika Pharmaceuticals BG, LTD, which is based in the European Union. This will allow NIKA to have a better operation efficiency in building the joint business model for the territories of Europe, Asia and Africa. Through Nika Pharmaceuticals BG, Nika BioTechnology and Nika Pharmaceuticals will jointly build a factory with manufacturing facilities for the production of various medicinal products and dietary supplements. The factory will also include both scientific and analytical laboratories, which would facilitate the creation of new drugs and ensure a high standard of quality control of production.
Mr. Savov stated, “We are convinced that with the development of the new business profile – model for growth of the company – we will achieve a successful, long lasting, sustainable development of Nika BioTechnology, Inc. (NIKA), which we would adhere to in the best interest of all shareholders in the company”.
Mr. Savov graduated from the Dimitar A. Tsenov Academy of Economics as a magister of economics with a specialty in accounting and control with a minor in finance. During the political changes in Bulgaria of November 10th, 1989, Savov started a private business by creating the first private petrol company and in a time of crisis with a lack of fuel, Savov built a chain of the first private and modern gas stations in Bulgaria named Elpida 3. He brought the company to a highly competitive level and practically saved Neftohim Burgas from bankruptcy and Bulgaria from a fuel shortage. For the past 25 years, Savov has funded and developed projects in the pharmaceutical field with the goal to provide medicine for treatment of various life-threatening diseases including AIDS, Cancer and others.
FORWARD LOOKING STATEMENT: Certain information set forth in this press release of Nika BioTechnology, Inc. contains “forward-looking information”. Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, (i) the expected development of the Company’s business, projects, and joint ventures; (ii) execution of the Company’s vision and growth strategy, including with respect to global growth; (iii) completion of the Company’s projects that are currently underway, in development or otherwise under consideration. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of the Nika BioTechnology, Inc. believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.